P&T Committee Meeting Information
Upcoming Meetings
Dates
- Tuesday, September 10, 2024; 12 p.m.-4 p.m.
- Wednesday, September 11, 2024; 9 a.m.-4 p.m.
Location
The September P&T Committee meetings will be held virtually
Register for the Webinars
- Register for DHS Pharmacy & Therapeutics Committee on September 10, 2024
- Register for DHS Pharmacy & Therapeutics Committee on September 11, 2024
Public Testimony
All members of the public may register to provide verbal or written testimony related to a drug or class of drugs included on the Statewide PDL at the P&T Committee meetings. Registration to present testimony during the meetings must be received by Tuesday, August 27, 2024. To register, please go to www.papdl.com and select "Public Testimony Registration." Written testimony will be accepted and must be submitted by Tuesday, August 27, 2024. Written testimony submissions will be distributed to all P&T Committee members prior to the meetings. All written testimony should be emailed to RA_PharmForms@pa.gov.
| Drug Classes | ||
|---|---|---|
Acne Agents, Oral | Colony Stimulating Factors | Migraine Acute Treatment Agents |
Acne Agents, Topical | Continuous Glucose Monitors Products | Migraine Prevention Agents |
Alcohol Use Disorder Agents | Contraceptives, Oral | Monoclonal Antibodies (MABs) – Anti-IL, Anti-IgE, Anti-TSLP |
Alzheimer’s Agents | Contraceptives, Other | Multiple Sclerosis Agents |
Analgesics, Non-Opioid Barbiturate Combinations | COPD Agents | Neuropathic Path Agents |
Analgesics, Opioid Long-Acting | Cytokine and CAM Antagonists | NSAIDs |
Analgesics, Opioid Short-Acting | Dry Eye Treatments | Obesity Treatment Agents |
Androgenic Agents | Enzyme Replacement, Gaucher Disease | Oncology Agents, Breast Cancer |
Angiotensin Modulator Combinations | Epinephrine, Self-Injected | Oncology Agents, Oral |
Angiotensin Modulators | Erythropoiesis Stimulating Agents | Ophthalmics, Allergic Conjunctivitis |
Antianginal Agents | Estrogens | Ophthalmics, Antibiotics |
Antibiotics, GI and Related Agents | Fluoroquinolones, Oral | Ophthalmics, Antibiotic-Steroid Combinations |
Antibiotics, Inhaled | GI Motility, Chronic Agents | Ophthalmics, Anti-Inflammatories |
Antibiotics, Topical | Glucocorticoids, Inhaled | Ophthalmics, Glaucoma |
Anticoagulants | Glucocorticoids, Oral | Opioid Overdose Agents |
Anticonvulsants | Growth Hormones | Opioid Use Disorder Treatments |
Antidepressants, Other | H. Pylori Treatments | Otic Antibiotic Preparations |
Antidepressants, SSRIs | Hematopoietic Mixtures | Pancreatic Enzymes |
Antiemetics/Antivertigo Agents | Hepatitis B Agents | Penicillins |
Antifibrotic Respiratory Agents | Hepatitis C Agents | Phosphate Lowering Agents |
Antifungals, Oral | Hereditary Angioedema (HAE) Agents | Pituitary Suppressive Agents, LHRH |
Antifungals, Topical | Histamine 2 Receptor Blockers | Platelet Aggregation Inhibitors |
Antihemophilia Agents | HIV/AIDS Antiretrovirals | Potassium Removing Agents |
Antihistamines, Minimally Sedating | Hypoglycemia Treatments | Prenatal Vitamins |
Antihypertensives, Sympatholytic | Hypoglycemics, Alpha-Glucosidase Inhibitors | Progestational Agents |
Antihyperuricemics | Hypoglycemics, Incretin Mimetics/Enhancers | Proton Pump Inhibitors (PPIs) |
Antimalarials | Hypoglycemics, Insulin and Related Agents | Pulmonary Hypertension Agents, Oral and Inhaled |
Antiparasitics, Topical | Hypoglycemics, Meglitinides | Sedative Hypnotics |
Antiparkinson’s Agents | Hypoglycemics, Metformins | Sickle Cell Anemia Agents |
Antipsoriatics, Oral | Hypoglycemics, SGLT2 Inhibitors | Skeletal Muscle Relaxants |
Antipsoriatics, Topical | Hypoglycemics, Sulfonylureas | Smoking Cessation Products |
Antipsychotics | Hypoglycemics, TZDs | Steroids, Topical |
Antivirals, CMV | Immunomodulators, Atopic Dermatitis | Stimulants and Related Agents |
Antivirals, Herpes | Immunomodulators, Topical | Tetracyclines |
Antivirals, Influenza | Immunosuppressives, Oral | Thalidomide and Derivatives |
Anxiolytics | Intra-Articular Hyaluronates | Thrombopoietics |
Benign Prostatic Hyperplasia (BPH) Treatments | Intranasal Rhinitis Agents | Thyroid Hormones |
Beta Blockers | Iron Chelating Agents | Tubeless Insulin Delivery Devices |
Bile Salts | Iron, Parenteral | Ulcerative Colitis Agents |
Bladder Relaxant Preparations | Leukotriene Modifiers | Urea Cycle Disorder Agents |
Blood Glucose Meters and Test Strips | Lipotropics, Other | Urinary Anti-Infectives |
Bone Density Regulators | Lipotropics, Statins | Vaginal Anti-Infectives |
Botulinum Toxins | Local Anesthetics, Topical | Vitamin D Analogs |
Bronchodilators, Beta Agonists | Macrolides | VMAT2 Inhibitors |
Calcium Channel Blockers | Macular Degeneration Agents |
|
Cephalosporins | Methotrexate |
|
- Past Pharmacy and Therapeutics Committee Meetings
- Review the Pharmacy and Therapeutics Committee By-Laws
Related Links
The Department of Human Services (Department) appointed the P&T Committee to act in an advisory capacity to the Department and the Office of Medical Assistance Programs (OMAP) and provide an unbiased clinical perspective on the Department's Statewide Preferred Drug List (PDL). Recommendations from the committee must be reviewed and approved by the Secretary of the Department of Human Services.
Change Healthcare provides clinical and financial analysis support to the P&T Committee.
Committee Information
Composition and responsibilities of the committee:
- Comprised of department medical directors, external physicians, pharmacists, consumer advocates, and specialists as needed for drug class reviews.
- Recommend a clinically-based PDL with an emphasis on effectiveness, safety, and outcomes.
- Recommend prior authorization guidelines for non-preferred drugs as well as certain preferred drugs using current community standards for prescribing.
- Recommend Prospective and Retrospective Drug Utilization Review Program Review and Development.
Name | Specialty | Independent* | Department** | MCO |
|---|---|---|---|---|
Ivonne Acrich, MD | Ad Hoc Child/Adolescent Psychiatrist |
| X |
|
Dale Adair, MD, FAPA | Office of Mental Health & Substance Abuse Services Medical Director | | X | |
Christopher Antypas, PharmD | Community Pharmacist | X |
|
|
Lawrence Appel, MD, SFHM | Medical Director, Office of Long Term Living |
| X |
|
Meghan Brenkle, PharmD | PA Health & Wellness Pharmacist | X | ||
Terri Cathers, PharmD, | OMAP Pharmacy Director |
| X |
|
Michael Colvin, PharmD | AmeriHealth Caritas & Keystone First HealthChoices & Community HealthChoices Pharmacist | | | X |
Sharon Connor, PharmD | Academic Pharmacist | X |
|
|
Molly DiMatteo, DO | Family Practitioner | X | | |
Oluwatoyin Fadeyibi, PharmD, MPH | Community Behavioral Health Pharmacist | | | X |
Andrea Fox, MD | Internist | X |
|
|
Mark Fuller, MD | Carelon Health of PA Medical Director | X | ||
Donald Gerhart, RPh | Community Pharmacist | X |
|
|
James Hancovsky, RPh, MBA | United Health Care Pharmacy Director |
|
| X |
David Kelley, MD | OMAP Chief Medical Officer, Office of Medical Assistance Programs | | X | |
Peter Kreckel, RPh | Community Pharmacist | X |
|
|
Renee Licwinko, RPh | Gateway Health Plan Pharmacist |
|
| X |
Michele Musheno, RPh, MS | Academic/Hospital Pharmacist | X |
|
|
Geoffrey Neimark, MD | Community Care Behavioral Health Psychiatrist | | | X |
Ian Paul, MD, Vice Chair | Pediatrician | X |
|
|
Adam Raphael Rom, MD | Family Practitioner | X |
|
|
Amy Saracino, DO | Ad Hoc Adult Psychiatrist |
| X |
|
| John Shand, MD | PerformCare PA Medical Director | X | ||
Christopher Squillaro, DO | Magellan Behavioral Health of PA Medical Director | | | X |
Kevin Szczecina, RPh | Geisinger Health Plan Pharmacist |
|
| X |
Fallan Vaisberg, PharmD, RPh | Health Partners Plans Formulary Pharmacist | | | X |
Andreas Wali, MD | Cardiologist | X | | |
Verlyn Warrington, MD | Bariatric Medicine Specialist/Family Medicine Doctor | X |
|
|
Lloyd Wertz | Consumer/Family Advocate | X |
|
|
Lauren Zandier, PharmD | UPMC For You Pharmacist | | | X |
Vacant | Consumer Representative | X |
|
|
* - Independent Members are not employed by the Department
** - Department Members are employed by the Department on a full or part-time basis
Effective July 2, 2024 / Last modified July 5, 2024